“Available data suggest that PCV7 may prove to be among the most reactogenic vaccine of those currently used, including the DTaP and Haemophilus conjugate vaccines.”
—American Academy of Pediatrics Journal of Pediatrics 2000; 106(2), 362-366.
S. pneumoniae is part of the body’s normal flora.308 In fact, over fifty percent of the population has these bacteria in their upper respiratory tract.309 It is only when the body’s normal flora is disrupted that infection results. Since the introduction of the Hib vaccine, S. pneumoniae has now become the leading cause of pneumonia in children under five.310
Children under two years of age are at the greatest risk for developing invasive pneumococcal infection; not healthy children, but children with an underlying disorder, such as sickle cell disease, HIV infection, Hodgkin’s disease, lymphoma, kidney disease, or conditions associated with immunosuppression—such as organ transplantation.311 The rate of invasive pneumococcal infections in 1998 was 188 cases per 100,000.312 On a population basis a child has a 99.812 percent chance of not contracting invasive pneumococcal infection, and a 99.9436 percent chance of not dying from the disease.
There have been over ninety serogroups of S. pneumoniae identified.313 The first pneumococcal vaccine was licensed in the United States in 1977 which contained fourteen different pneumococcal serogroups.314 It was worthless and replaced with another vaccine in 1983 which contained twenty-three different pneumococcal serogroups.315 This vaccine too, is essentially worthless. According to the CDC, individuals “with some chronic illnesses or immunodeficiency may not respond as well, if at all. In children less than 2 years of age, antibody responses to most serotypes are generally poor.”316-317 And this is the vaccine that is supposed to protect children under two and the immunocompromised from pneumococcal infection?
Another pneumococcal vaccine (Prevnar®) was licensed in the U.S. in 2000.318 This vaccine contains seven different pneumococcal serogroups.319 The vaccine has an 89 percent failure rate at “reducing clinically diagnosed pneumonia.”320
Prevnar® has not been tested for its safety either. During the vaccine safety trials Prevnar® was compared to an investigational meningococcal group C vaccine.321 There have been no safety studies performed comparing Prevnar® to a placebo, only studies comparing Prevnar® to other vaccines.322 This is just one more example of how children are used as little white rabbits.
